No Data
VTR Bio-Tech to Redeem Convertible Bonds of 665 Million Yuan
Guangdong Vtr Bio-Tech (300381.SZ): Jindadi Investment has cumulatively reduced its shareholding by 1.94%.
On December 15, Gelonghui reported that Guangdong Vtr Bio-Tech (300381.SZ) announced that on December 13, 2024, the company received a notice from Jinda Di Investment regarding the completion of the shareholding reduction plan. On December 12, 2024, Jinda Di Investment reduced its shareholding by 720,000 shares through a block trade, accounting for 0.15% of the company's total share capital after deducting shares held in the company's repurchase special securities account. As of the date of this announcement, Jinda Di Investment has cumulatively reduced its shareholding by 9,309,000 shares, accounting for 1.94% of the company's total share capital after deducting shares held in the company's repurchase special securities account.
Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged CN¥398m Last Week
Profit: Report for the third quarter of 2024
Guangdong VTR Bio-Tech (300381.SZ) released its performance for the first three quarters, with a net income of 42.7988 million yuan, an increase of 245.33%.
Guangdong VTR Bio-Tech (300381.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved a revenue of 6...
Guangdong VTR Bio-Tech (300381.SZ): net income in the third quarter was 1.0152 million yuan, a year-on-year decrease of 79.64%.
Guangdong VTR Bio-Tech (300381.SZ) announced its third quarter report for 2024 on October 22nd. During the reporting period, the revenue was 0.211 billion yuan, a decrease of 3.52% year-on-year. The net income attributable to shareholders of the listed company was 1.0152 million yuan, a decrease of 79.64% year-on-year. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was -4.832 million yuan. Basic earnings per share were 0.0021 yuan.
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Not Doing Enough For Some Investors As Its Shares Slump 27%
